Female Fertility and Pregnancy Rapid Test Market Overview
The global female fertility and pregnancy rapid test market is expected to generate $489.3 million by 2022, advancing at a CAGR of 4.5% during the forecast period (2016–2022). The factors such as rising female aging population, surging number of infertility cases, and rising prevalence of uterine malformations are expected to drive the growth of the market. In addition, rising demand for home-use diagnostic devices is also expected to fuel the market growth in the coming years.
Based on product, the female fertility and pregnancy rapid test market is categorized into strips/dipsticks, cards/cassettes, and midstreams. Among these, the strips/dipsticks category is expected to lead the market in the coming years, with an expected contribution of 50.2% share by 2022. Whereas, the market for midstream products is expected to witness the fastest growth during the forecast period.
The female fertility and pregnancy rapid test market is categorized into follicle stimulating hormone (FSH), luteinizing hormone (LH), and human chorionic gonadotropin (HCG), based on the type of test. Among these, the LH category is projected to lead the market throughout the analysis period. The category is also expected to hold 42.0% share by 2022 in the market.
Globally, North America will lead the female fertility and pregnancy rapid test market throughout the analysis period. Increasing aging female population is an important factor driving the growth of the market in the region, as the aged females are more prone to disorders, such as polycystic ovary syndrome (PCOS) and fibroids, which lead to high demand for hormone testing products. The female population is the region is increasingly experiencing hormonal imbalances, such as irregular and heavy bleeding, indescribable miscarriages, and abnormalities of uterus, which in turn, will generate high demand for fertility and pregnancy rapid testing products in the coming years.
Female Fertility and Pregnancy Rapid Test Market Dynamics
The increasing adoption of home-based diagnostic testing products is driving the growth of the female fertility and pregnancy rapid test market, as these products are easy-to-use and save patients from opting for laboratory tests. Besides, these products are also cost-effective and can be easily used by the patients at-home. Thus, rise in the demand for at-home diagnostic devices is an important factor that will immensely drive the market in the coming years.
Further, rising healthcare expenditure is fueling the growth of the female fertility and pregnancy rapid test market, across the globe, as large amount of money is being spent on healthcare by various countries that provides improved accessibility of advanced medical treatments to patients. Further, increasing prevalence of various diseases and subsequently the introduction of diagnostic products with advanced features are expected to boost the demand for fertility and pregnancy rapid test kits.
High cost and availability of alternative diagnostic methods are likely to hamper the growth of the female fertility and pregnancy rapid test market. For instance, midstream products available in the market are costly, compared to strips/dipsticks and cassettes/cards. Hence, patients mainly opt for the latter, which may lead to reduce the adoption of the midstream products.
Besides, preference for several tests, such as blood test and laboratory-based tests, is also impeding the female fertility and pregnancy rapid test market growth, as these tests are performed by skilled professionals and provide accurate results, and therefore, are highly preferred by patients. On the other hand, strips/dipsticks and cassettes/cards do not provide accurate results at all times. Also, limited awareness about these products, especially in the developing economies will also hamper the growth of the market.
Female Fertility and Pregnancy Rapid Test Market Competitive Landscape
Key players operating in the global female fertility and pregnancy rapid test market include Atlas Medical, Alere Inc., BioMerieux SA, Diagnostic Automation/Cortez Diagnostics Inc., Church & Dwight Co. Inc., SA Scientific, Gemc Technology Group Co. Ltd., and Nantong Egens Biotechnology Co. Ltd.
Key Questions Answered in the Report
What is the current scenario of the global female fertility and pregnancy rapid test market?
What are the emerging technologies for the development of female fertility and pregnancy rapid test products?
What are the key market segments and their market size and future potential?
What are the major catalysts for the market and their impact during the short, medium, and long terms?
What are the evolving opportunities for the players in the market?
What are the key regions from the investment perspective?
What are the key strategies adopted by the major players to expand their market shares?